Consensus Gilead Sciences, Inc.

Stocks

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 00:00:00 10/10/2026 +04			5-day change	1st Jan Change
151.17 ^USD	+2.77%		+4.44%	+23.16%

10-08	RBC Lifts Price Target on Gilead Sciences to $126 From $123, Keeps Sector Perform Rating	MT
10-07	Pharmaceutical Group Sues US Government Over Medicare Drug Pricing Rule	MT

Evolution of the Average Target: Gilead Sciences, Inc.

Evolution of the Target Price: Gilead Sciences, Inc.

Changes in Analyst Recommendations: Gilead Sciences, Inc.

69d63.hPA_a9SRu7B58RAbkqR7NjAnKF96r_SH6vDdM3Ez5Uw.15tNXqak0_MBtlt-1u0UeXl-GD0T37v_rL2bQDdenAXXgGUh5_rpxjWDXQ~08c9243633df637b16bf82e1fcd68547

Analysts' recommendations: Gilead Sciences, Inc.

10-08	RBC Lifts Price Target on Gilead Sciences to $126 From $123, Keeps Sector Perform Rating	MT
10-07	Morgan Stanley Adjusts Price Target on Gilead Sciences to $163 From $165	MT
10-07	JPMorgan Adjusts Price Target on Gilead Sciences to $170 From $160	MT
10-02	Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says	MT
09-10	HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating	MT
08-05	Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says	MT
08-05	Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126	MT
08-05	Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130	MT
08-05	RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating	MT
08-04	Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says	MT
07-28	Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating	MT
07-23	Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating	MT
07-21	Gilead Sciences Shares Fall After Downgrade From Leerink Partners	MT
07-21	Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike…
07-21	Leerink Partners Downgrades Gilead Sciences to Market Perform From Outperform, Adjusts PT to $127 From $146	MT
07-08	Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says	MT
07-08	Morgan Stanley Adjusts Price Target Gilead Sciences to $166 From $168, Maintains Overweight Rating	MT
07-07	Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157	MT
07-07	RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating	MT
07-06	Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow…
07-06	HSBC Upgrades Gilead Sciences to Buy From Hold, Adjusts Price Target to $155 From $133	MT
06-08	Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says	MT
05-20	Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target is $165	MT
05-19	Daiwa Securities Adjusts PT on Gilead Sciences to $150 From $161, Maintains Outperform Rating	MT
05-11	Gilead's Emvistegrast Readout Unlikely to Move Stock, RBC Says	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	GILEAD SCIENCES, INC.					+5.43%
	ELI LILLY AND COMPANY					+12.79%
	JOHNSON & JOHNSON					+7.03%
	ABBVIE INC.					+2.22%
	MERCK & CO., INC.					+8.71%
	ROCHE HOLDING AG					+5.14%
	NOVARTIS AG					+4.76%
	ASTRAZENECA PLC					+31.69%
	AMGEN INC.					-4.73%
	NOVO NORDISK A/S					+20.08%
	Average					+9.31%
	Weighted average by Cap.					+9.14%